Histologic heterogeneity predicts patient prognosis of HER2-positive metastatic breast cancer: A retrospective study based on SEER database.

Yajie WangYiran LiangFangzhou YeDan LuoYuhan JinYaming LiWenjing ZhaoBing ChenLijuan WangQifeng Yang

Published in: Cancer medicine (2023)

Histological subtypes are involved in determining the heterogeneity of HER2+ MBC patient prognosis, which is helpful to guide the prognosis prediction and monitoring of HER2+ breast cancer patients in clinics.

Keyphrases

metastatic breast cancer
case report
single cell
primary care
emergency department
adverse drug